Male-pattern hair loss (androgenetic alopecia) is driven largely by a single hormone acting on genetically susceptible follicles. Finasteride and dutasteride are the two oral drugs that target the enzyme responsible. They are the most studied medical treatments for the condition, and they also come up constantly in the looksmaxing and steroid-using communities because the same androgen pathway that builds muscle can accelerate scalp thinning. This guide walks through the mechanism, the real efficacy data, and the safety questions that generate the most argument online.
The DHT mechanism in plain terms
Testosterone is converted in the skin, scalp, and prostate into dihydrotestosterone (DHT), a more potent androgen, by the enzyme 5-alpha-reductase. DHT binds the androgen receptor in hair follicles and, in people with the genetic predisposition, gradually miniaturizes them: each growth cycle produces a finer, shorter, less pigmented hair until the follicle effectively stops producing visible hair. There are two main relevant isoenzymes. Type 2 predominates in scalp and prostate; type 1 is more widespread in skin and sebaceous glands. This split matters because the two drugs hit them differently.
What finasteride and dutasteride actually do
- Finasteride selectively inhibits type 2 5-alpha-reductase. At the standard 1 mg/day hair dose it lowers serum DHT by roughly 65-70%.
- Dutasteride inhibits both type 1 and type 2. At 0.5 mg/day it suppresses serum DHT by around 90% or more, a deeper and more complete blockade.
- Neither drug touches testosterone meaningfully at these doses; serum testosterone typically rises slightly because less is being converted to DHT. This is why they are androgen-pathway drugs, not anti-testosterone drugs.
- Both take months to show effect. Follicles that have been shrinking need time to re-enter and complete healthy growth cycles, so 6-12 months is the honest timeline before judging results, and a mild early shed is common.
The efficacy numbers
Finasteride 1 mg is FDA-approved for male pattern hair loss on the strength of large randomized trials. In the pivotal studies, roughly two-thirds of men had visible regrowth by objective hair count and the large majority stopped further loss over 1-2 years, versus continued decline on placebo. The realistic framing is that finasteride is very good at halting or slowing loss and moderately good at partial regrowth, especially at the crown.
Dutasteride is approved for hair loss in some countries (notably South Korea and Japan) but is used off-label for it elsewhere. Head-to-head trials and meta-analyses consistently show dutasteride 0.5 mg produces somewhat greater hair counts than finasteride 1 mg, consistent with its deeper DHT suppression. The trade-off is that it is a stronger, longer-acting drug (its half-life is measured in weeks, not hours), so any side effects can persist longer after stopping.
The side-effect question
The commonly cited sexual side effects are reduced libido, erectile difficulty, and reduced ejaculate volume. In controlled trials these occurred in a low single-digit percentage of men and only modestly above placebo, and most cases resolved on continuing or stopping the drug. That is the trial-level reality. It coexists with a large body of individual reports of more troubling or persistent effects, which is where the debate lives.
- Sexual effects (libido, erectile function, ejaculate) are the best-documented and are usually reversible.
- Gynecomastia and breast tenderness are uncommon but reported.
- Mood changes and depressive symptoms have been reported and are still being studied; regulators in several countries have updated labels to mention depression and, in some, suicidal ideation.
- Finasteride lowers PSA (prostate-specific antigen) by roughly half, which must be accounted for in prostate cancer screening.
Post-finasteride syndrome: what is and isn't established
Post-finasteride syndrome (PFS) is the term for persistent sexual, physical, or neuropsychiatric symptoms that some men report continuing after stopping the drug. It is a genuinely contested topic and both extreme positions overstate their case. What can be said fairly:
- Large clinical trials and most pharmacovigilance analyses do not show a clear, consistent signal that a distinct persistent syndrome affects a measurable fraction of users; reported persistent cases are rare relative to total prescriptions.
- At the same time, the persistent cases are real to the people experiencing them, the phenomenon has not been definitively explained or ruled out, and self-selected online and registry data cannot establish incidence.
- There is no validated diagnostic test or proven treatment for PFS, and no reliable way to predict who might be affected.
- Honest bottom line: the probability appears low, the severity in affected individuals can be high, and the science is unsettled. That risk profile is exactly why it deserves a real conversation rather than dismissal or panic.
Practical considerations for the androgen-using audience
Men on anabolic steroids often experience accelerated hair loss because supraphysiological androgens drive more DHT and more receptor activation. A 5-alpha-reductase inhibitor can blunt this, but it only addresses the DHT-mediated component; potent non-aromatizing or DHT-derived compounds can still thin hair through direct androgen-receptor activity that finasteride does not block. Some also worry about combining a systemic anti-DHT drug with a performance goal that depends on androgens; the DHT reduction does not meaningfully reduce muscle-building at these doses, but it is a real consideration for anyone valuing every androgenic pathway.
Bottom line
Finasteride and dutasteride are the most effective and best-evidenced oral treatments for male-pattern hair loss, working by cutting DHT. Finasteride halts loss in most men and regrows hair in a majority over a year; dutasteride is modestly stronger but longer-acting. Sexual side effects are uncommon and usually reversible in trials, while post-finasteride syndrome remains a low-probability, unresolved concern that is worth understanding before starting. This is reference information, not medical advice.